| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |